[{"data":1,"prerenderedAt":219},["ShallowReactive",2],{"drug-etanercept":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":45,"contraindications":105,"warnings":115,"renal":123,"monitoring":124,"interactions":125,"review":126,"examples":129,"atc":136,"iran":138,"usApproval":162,"links":168,"populations":185},"etanercept",1,{"fa":7,"en":8},"اتانرسپت","Etanercept","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده TNF","TNF blocker",[14],{"name":15,"market":16},"Enbrel","US",[18,19,7,20,21],"enbrel","انبرل","altebrel","آلتبرل",[23,36],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32},"syr-50","injection","sc","50 mg\u002FmL prefilled syringe or autoinjector",{"amount":29,"unit":30,"perVolumeMl":5},50,"mg",[16],[33],{"source":34,"section":35},"fda-enbrel","3",{"id":37,"form":25,"route":26,"label":38,"concentration":39,"markets":42,"refs":43},"vial-25","25 mg\u002F0.5 mL single-dose vial",{"amount":40,"unit":30,"perVolumeMl":41},25,0.5,[16],[44],{"source":34,"section":35},[46,64,78],{"id":47,"disease":48,"label":49,"population":52,"type":56,"unit":30,"dose":57,"refs":61},"ra","rheumatoid-arthritis",{"fa":50,"en":51},"آرتریت روماتوئید، پسوریاتیک، اسپوندیلیت — ۵۰ mg هفته‌ای یک بار","RA, PsA, ankylosing spondylitis — 50 mg once WEEKLY",{"minAge":53},{"value":54,"unit":55},18,"year","notCalculated",{"reason":58},{"fa":59,"en":60},"هفته‌ای یک بار ۵۰ mg زیرجلدی (نه روزانه)، با یا بدون متوترکسات.","50 mg SC once WEEKLY (not daily), with or without methotrexate.",[62],{"source":34,"section":63},"2",{"id":65,"disease":66,"label":67,"population":70,"type":56,"unit":30,"dose":72,"refs":76},"pso","psoriasis",{"fa":68,"en":69},"پسوریازیس پلاک بزرگسال — ۵۰ mg دو بار در هفته ۳ ماه، سپس هفته‌ای یک بار","Adult plaque psoriasis — 50 mg twice weekly for 3 months, then once weekly",{"minAge":71},{"value":54,"unit":55},{"reason":73},{"fa":74,"en":75},"۵۰ mg دو بار در هفته به مدت ۳ ماه، سپس ۵۰ mg هفته‌ای یک بار.","50 mg twice weekly for 3 months, then 50 mg once weekly.",[77],{"source":34,"section":63},{"id":79,"disease":80,"label":81,"population":84,"type":86,"unit":30,"dose":87,"refs":90,"limits":93,"durationDays":96,"allowedFormulations":97,"notes":98},"jia","juvenile-arthritis",{"fa":82,"en":83},"pJIA، پسوریازیس و JPsA کودک — ۰٫۸ mg\u002Fkg هفته‌ای یک بار (حداکثر ۵۰ mg)","pJIA, pediatric psoriasis and JPsA — 0.8 mg\u002Fkg once weekly (max 50 mg)",{"maxAge":85},{"value":54,"unit":55},"weightBased",{"perKgPerDose":88,"intervalHours":89},0.8,24,[91],{"source":34,"section":92},"2.4",{"maxPerDose":29,"refs":94},[95],{"source":34,"section":92},{"min":5,"max":5},[37],[99],{"text":100,"refs":103},{"fa":101,"en":102},"یک دوز در هفته (نه روزانه). ۶۳ kg یا بیشتر: ۵۰ mg هفتگی. برای دوزهای غیر از ۲۵ یا ۵۰ mg از ویال استفاده شود.","One dose per WEEK (not daily). ≥63 kg: 50 mg weekly. Use the vial for doses other than 25 or 50 mg.",[104],{"source":34,"section":92},[106],{"id":107,"severity":108,"text":109,"refs":112},"sepsis","block",{"fa":110,"en":111},"سپسیس.","Sepsis.",[113],{"source":34,"section":114},"4",[116],{"text":117,"refs":120},{"fa":118,"en":119},"هشدار جعبه‌ای: عفونت جدی (سل، قارچی، فرصت‌طلب) و بدخیمی. پیش از شروع تست سل نهفته و در صورت مثبت بودن درمان آن.","Boxed warning: serious infections (TB, fungal, opportunistic) and malignancy. Test for latent TB before starting and treat if positive.",[121],{"source":34,"section":122},"Boxed Warning",[],[],[],{"status":127,"reviewer":128,"date":128},"unverified",null,[130],{"regimen":79,"formulation":37,"input":131,"expect":133},{"ageYears":132,"weightKg":40},8,{"perDose":134,"mlPerDose":135},20,0.4,[137],"L04AB01",{"status":139,"forms":140,"refs":157},"registered",[141,145,149,153],{"code":142,"en":143,"fa":144},"04008","ETANERCEPT 25MG VIAL","ویال اتانرسپت ۲۵ میلی‌گرم",{"code":146,"en":147,"fa":148},"21559","ETANERCEPT 50MG PREFILLED SYRINGE","سرنگ از پیش پرشده اتانرسپت ۵۰ میلی‌گرم",{"code":150,"en":151,"fa":152},"08170","ETANERCEPT 50MG VIAL","ویال اتانرسپت ۵۰ میلی‌گرم",{"code":154,"en":155,"fa":156},"52294","ETANERCEPT INJECTION, SOLUTION SUBCUTANEOUS 25 mg\u002F0.5mL","فرآورده تزریقی اتانرسپت ۲۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",[158],{"source":159,"section":160,"url":161},"darooyab-generic","G-68\u002FEtanercept","https:\u002F\u002Fwww.darooyab.ir\u002FG-68\u002FEtanercept",{"kind":163,"refs":164,"id":167},"BLA",[165],{"source":34,"section":166},"SPL approval \u002F marketing category","BLA103795",[169,172,176,180,183],{"kind":170,"url":171,"label":167},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=103795",{"kind":173,"url":174,"label":175},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=a002b40c-097d-47a5-957f-7a7b1807af7f","FDA Enbrel",{"kind":177,"url":178,"label":179},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa602013.html","Etanercept Injection",{"kind":181,"url":182,"label":137},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L04AB01",{"kind":184,"url":161,"label":8},"darooyab",{"pregnancy":186,"lactation":195,"pediatric":203,"geriatric":211},{"level":187,"text":188,"quote":191,"refs":192},"caution",{"fa":189,"en":190},"برچسب: مطالعات موجود ارتباط قابل‌اعتمادی با نقص مادرزادی بزرگ نشان نمی‌دهند.","Label: available studies do not reliably support an association with major birth defects.","Available studies with use of etanercept during pregnancy do not reliably support an association between etanercept and major birth defects.",[193],{"source":34,"section":194},"8.1",{"level":187,"text":196,"quote":199,"refs":200},{"fa":197,"en":198},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Data from published literature show that etanercept is present in low levels in human milk but is not detected in the plasma of breastfed infants (see Data ) .",[201],{"source":34,"section":202},"8.2",{"level":187,"text":204,"quote":207,"refs":208},{"fa":205,"en":206},"برچسب: در pJIA از ۲ سالگی ثابت شده؛ هشدار جعبه‌ای لنفوم و بدخیمی در کودکان و نوجوانان.","Label: established for pJIA from 2 y; boxed warning of lymphoma and malignancy in children and adolescents.","The safety and effectiveness of Enbrel have been established in pediatric patients 2 years of age and older with pJIA.",[209],{"source":34,"section":210},"8.4",{"level":187,"text":212,"quote":215,"refs":216},{"fa":213,"en":214},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.",[217],{"source":34,"section":218},"8.5",1792156177664]